Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
16 (12) e76007
Multiple pharmacies, not one
Adverse effects observed in trials to date include: Gastrointestinal symptoms nausea, vomiting, diarrhoea, and constipation (common with GLP-1 receptor agonists) Reduced appetite and weight loss , which may be excessive in some individuals Elevated heart rate , a concern noted with glucagon receptor agonism As with other incretin-based therapies, there is also a class-level signal for acute pancreatitis and gallbladder disease (including cholelithiasis and cholecystitis)
"Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial." Eli Lilly and Company, 11 Dec
US$ 29.70
US$ 25.71
US$ 26.48
US$ 28.59
US$ 24.53
